Natixis Iovance Biotherapeutics, Inc. Transaction History
Natixis
- $20.7 Billion
- Q3 2025
A detailed history of Natixis transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Natixis holds 20,479 shares of IOVA stock, worth $50,583. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,479
Previous 44,280
53.75%
Holding current value
$50,583
Previous $76,000
42.11%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding IOVA
# of Institutions
290Shares Held
219MCall Options Held
2.41MPut Options Held
1.7M-
Mhr Fund Management LLC New York, NY29MShares$71.5 Million10.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.1MShares$59.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$52.4 Million0.0% of portfolio
-
State Street Corp Boston, MA13.3MShares$32.9 Million0.0% of portfolio
-
Invenomic Capital Management LP Boston, MA10.5MShares$26 Million1.15% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $390M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...